Jasper Therapeutics Inc. (JSPR)
Jasper Therapeutics Inc. (JSPR) Stock Price, Analysis & Data
| Bid | n/a |
| Market Cap | 27.25M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -55.73M |
| Beta | 3.03 |
| EPS (ttm) | -0.93 |
| PE Ratio (ttm) | n/a |
| Forward PE | -0.32 |
| P/B (ttm) | 6.77 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 10, 2026 |
| Ask | n/a |
| Volume | 441,159 |
| Avg. Volume (20D) | 1,464,843 |
| Open | 0.77 |
| Previous Close | 0.79 |
| Day's Range | 0.75 - 0.88 |
| 52-Week Range | 0.32 - 3.13 |
| Analyst | Buy |
| Price Target | 6 (631.71%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About JSPR
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with v...
Financial Performance
In 2025, Jasper Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -75.8M, an increase of 6.36%.
Financial StatementsAnalyst Forecast
According to 3 analyst ratings, the average rating for JSPR stock is "Buy". The 12-month stock price forecast is 6, which is upside of 631.71% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
